menu
    • menu

    Company profile for Dracen Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types. Our goal in treating cancers is to directly shrink tumors and remodel the tumor microenvironment to make it more conducive to immuno-oncology approaches, to gain greater disease control, increase anti-tumor responses and extend patient survival in areas of unmet need...
    Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types. Our goal in treating cancers is to directly shrink tumors and remodel the tumor microenvironment to make it more conducive to immuno-oncology approaches, to gain greater disease control, increase anti-tumor responses and extend patient survival in areas of unmet need. This includes cancers that possess genetic mutations which may make them highly susceptible to our therapies and those able to evade available immuno-oncology and other standard-of-care approaches.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dracen PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    780 Third Ave 45th Floor New York, NY 10017
    Telephone
    Telephone
    (917) 398-3710
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dracenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dracen-pharmaceuticals-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021
    Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021

    03 Jun 2021

    // PRWEB

    https://www.prweb.com/releases/dracen_announces_drp_104_sirpiglenastat_presentation_at_asco_2021_virtual_annual_meeting/prweb17979847.htm

    PRWEB
    03 Jun 2021
    Share Share
    Dracen Announces Clinical Collaboration with Merck
    Dracen Announces Clinical Collaboration with Merck

    08 Mar 2021

    // PRWEB

    https://www.prweb.com/releases/dracen_announces_clinical_collaboration_with_merck/prweb17775654.htm

    PRWEB
    08 Mar 2021
    Share Share
    Dracen DRP-104 Granted U.S. FDA Fast Track Designation for the treatment
    Dracen DRP-104 Granted U.S. FDA Fast Track Designation for the treatment

    27 Oct 2020

    // PRWEB

    https://www.prweb.com/releases/dracen_pharmaceuticals_drp_104_granted_u_s_fda_fast_track_designation_for_the_treatment_of_non_small_cell_lung_cancer/prweb17497203.htm

    PRWEB
    27 Oct 2020
    Share Share
    Dracen Pharma Announces the Initiation of First-in-human Study of DRP-104
    Dracen Pharma Announces the Initiation of First-in-human Study of DRP-104

    25 Sep 2020

    // PRWEB

    https://www.prweb.com/releases/dracen_pharmaceuticals_announces_the_initiation_of_first_in_human_study_of_drp_104_in_adult_patients_with_advanced_solid_tumors/prweb17423191.htm

    PRWEB
    25 Sep 2020
    Share Share
    DRACEN ANNOUNCES TWO DRP-104 PRESENTATIONS AT AACR
    DRACEN ANNOUNCES TWO DRP-104 PRESENTATIONS AT AACR

    05 Apr 2020

    // DRACENPHARMA

    https://www.dracenpharma.com/dracen-announces-two-drp-104-presentations-at-aacr/

    DRACENPHARMA
    05 Apr 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search